Thyrotoxic Storm Following Thyroidectomy Medication

  • Author: Nafisa K Kuwajerwala, MD; Chief Editor: Arlen D Meyers, MD, MBA   more...
 
Updated: Apr 26, 2010
 

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Next

Antithyroid agents

Class Summary

These agents block thyroid hormone synthesis.

Propylthiouracil (PTU)

 

Thiourea agent that blocks production of thyroid hormones. In addition, inhibits peripheral deiodination of T4 to T3. Preferred over MMI in thyroid storm.

Methimazole (Tapazole)

 

Active moiety of parent compound carbimazole. Blocks incorporation of iodine into thyroglobulin within 1 h of ingestion.

Methimazole was initially thought to be associated with neonatal aplasia cutis (ie, defect in the neonatal scalp) and was thought to be more likely to cross the placenta than PTU. However, recent studies by Wing et al concluded that PTU and MMI are equally effective and safe in the treatment of hyperthyroidism in pregnancy.

Lithium (Eskalith, Lithotabs)

 

Used in patients intolerant to iodine; impairs thyroid hormone release.

Potassium Iodide (Thyro-Block, Pima)

 

Inhibits thyroid hormone secretion. Contains 8 mg of iodide per drop. May be mixed with juice or water for intake.

Iodide treatment is reserved for the treatment of thyroid storm. It is also used for 10-14 d prior to surgical procedure, including thyroidectomy. Can be used with Graves thyrotoxicosis but exacerbates thyrotoxicosis from toxic multinodular goiter and toxic adenoma.

Sodium ipodate (Oragrafin)

 

One of the most effective inhibitors of deiodinase, which converts T4 to the more biologically active T3. Reduction in conversion of T4 to T3 can greatly reduce T3 levels and thyrotoxic symptoms.

Previous
Next

Glucocorticoids

Class Summary

These agents reduce iodine uptake and antibody titers of thyroid-stimulating antibodies with stabilization of the vascular bed.

Dexamethasone (Decadron, Dexone)

 

Has many pharmacologic benefits but significant adverse effects. Stabilizes cell and lysosomal membranes, increases surfactant synthesis, increases serum vitamin A concentration, and inhibits prostaglandin and proinflammatory cytokines (eg, TNF-alpha, IL-6, IL-2, IFN-gamma). The inhibition of chemotactic factors and factors that increase capillary permeability inhibits recruitment of inflammatory cells into affected areas. Suppresses lymphocyte proliferation through direct cytolysis and inhibits mitosis. Breaks down granulocyte aggregates and improves pulmonary microcirculation. Has inhibitory effect on conversion of T4 to T3.

Adverse effects include hyperglycemia, hypertension, weight loss, GI bleeding or perforation synthesis, cerebral palsy, adrenal suppression, and death. Most of the adverse effects of corticosteroids are dose dependent or duration dependent.

Readily absorbed via the GI tract and metabolized in the liver. Inactive metabolites are excreted via the kidneys. Lacks salt-retaining property of hydrocortisone.

Patients can be switched from an IV to PO regimen in a 1:1 ratio.

Hydrocortisone (Cortef, Solu-Cortef)

 

Elicits anti-inflammatory properties and causes profound and varied metabolic effects. Modifies the body's immune response to diverse stimuli.

Previous
Next

Analgesics

Class Summary

Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties.

Acetaminophen (Feverall, Panadol)

 

Inhibits action of endogenous pyrogens on heat-regulating centers; reduces fever by a direct action on the hypothalamic heat-regulating centers, which, in turn, increases the dissipation of body heat via sweating and vasodilation.

Previous
Next

Beta-adrenergic blockers

Class Summary

These agents inhibit chronotropic, inotropic, and vasodilatory responses to beta-adrenergic stimulation.

Propranolol (Inderal, Betachron E-R)

 

DOC to counter peripheral action of thyroid hormone; blocks beta-adrenergic receptors; prevents conversion of T4 to T3.

Esmolol (Brevibloc)

 

Ultra–short-acting agent that selectively blocks beta1-receptors with little or no effect on beta2-receptor types. Particularly useful in patients with elevated arterial pressure, especially if surgery is planned. Shown to reduce episodes of chest pain and clinical cardiac events compared with placebo. Used successfully in thyrotoxicosis and thyroid storm. Can be discontinued abruptly if necessary.

Useful in patients at risk for experiencing complications from beta-blockade; particularly those with reactive airway disease, mild-moderate LV dysfunction, and/or peripheral vascular disease. Short half-life of 8 min allows for titration to desired effect and quick discontinuation if needed.

Previous
Next

Antihypertensive agents

Class Summary

These agents reduce blood pressure.

Guanethidine (Ismelin)

 

For use in patients with congestive cardiac failure, bronchospasm, or history of asthma.

Reserpine

 

For use in patients with congestive cardiac failure, bronchospasm, or history of asthma; successful treatment has been documented in cases of thyroid storm resistant to large doses of propranolol.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Nafisa K Kuwajerwala, MD  Staff Surgeon, Breast Care Center, William Beaumont Hospital

Nafisa K Kuwajerwala, MD is a member of the following medical societies: American College of Surgeons, American Society of Breast Disease, and American Society of Breast Surgeons

Disclosure: Nothing to disclose.

Coauthor(s)

Gunateet Goswami, MD  Consulting Staff, Internal Medicine Associates, Mount Clemens, Michigan; Consulting Staff, Department of Cardiology, Henry Ford Hospital

Gunateet Goswami, MD is a member of the following medical societies: American Medical Association, American Society of Echocardiography, and Michigan State Medical Society

Disclosure: Nothing to disclose.

Thabet Abbarah, MD, FACS  Consulting Staff, Department of Otolaryngology, North Oakland Medical Centers

Thabet Abbarah, MD, FACS is a member of the following medical societies: American College of Surgeons

Disclosure: Nothing to disclose.

Venkata Subramanian Kanthimathinathan, MD  Staff Physician, Department of General Surgery, Loma Linda University Medical Center

Disclosure: Nothing to disclose.

Pankaj Chaturvedi, MBBS, MS  Associate Professor, Head and Neck Surgery, Department of Surgical Oncology, Tata Memorial Hospital, India

Pankaj Chaturvedi, MBBS, MS is a member of the following medical societies: American Association for the Advancement of Science, American Head and Neck Society, Association of Surgeons of India, and Indian Academy of Tropical Parasitology

Disclosure: Nothing to disclose.

Specialty Editor Board

Mimi S Kokoska, MD  Associate Professor, Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences; Chief, Department of Otolaryngology-Head and Neck Surgery, Central Arkansas Veterans Healthcare System

Mimi S Kokoska, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American College of Physician Executives, American College of Surgeons, American Head and Neck Society, and Arkansas Medical Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Dean Toriumi, MD  Associate Professor, Department of Otolaryngology, University of Illinois Medical Center

Disclosure: Nothing to disclose.

Christopher L Slack, MD  Private Practice in Otolaryngology and Facial Plastic Surgery, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders

Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA  Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society

Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation Unrestricted gift Unknown; Axis Three Corporation Ownership interest Consulting; Omni Biosciences Ownership interest Consulting; Sentegra Ownership interest Board membership; Syndicom Ownership interest Consulting; Oxlo Consulting; Medvoy Ownership interest Management position; Cerescan Imaging Honoraria Consulting; GYRUS ACMI Honoraria Consulting

References
  1. Lahey FH. Apathetic thyroidism. Ann Surg. 1931;93:1026-30.

  2. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. Jun 1993;22(2):263-77. [Medline].

  3. Martin D. Disseminated intravascular coagulation precipitated by thyroid storm. South Med J. Feb 2009;102(2):193-5. [Medline].

  4. Brooks MH, Waldstein SS, Bronsky D, Sterling K. Serum triiodothyronine concentration in thyroid storm. J Clin Endocrinol Metab. Feb 1975;40(2):339-41. [Medline].

  5. Ecker JL, Musci TJ. Treatment of thyroid disease in pregnancy. Obstet Gynecol Clin North Am. Sep 1997;24(3):575-89. [Medline].

  6. Gavin LA. Thyroid crises. Med Clin North Am. Jan 1991;75(1):179-93. [Medline].

  7. Ingbar SH. Management of emergencies. IX. Thyrotoxic storm. N Engl J Med. Jun 2 1966;274(22):1252-4. [Medline].

  8. Mackin JF, Canary JJ, Pittman CS. Thyroid storm and its management. N Engl J Med. Dec 26 1974;291(26):1396-8. [Medline].

  9. Mazzaferri EL, Skillman TG. Thyroid storm. A review of 22 episodes with special emphasis on the use of guanethidine. Arch Intern Med. Dec 1969;124(6):684-90. [Medline].

  10. Migneco A, Ojetti V, Testa A. Management of thyrotoxic crisis. Eur Rev Med Pharmacol Sci. Jan-Feb 2005;9(1):69-74. [Medline].

  11. Milham S Jr. Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy. Teratology. Oct 1985;32(2):321. [Medline].

  12. Nakamura S, Nishmyama T, Hanaoka K. [Perioperative thyroid storm in a patient with undiscovered hyperthyroidism]. Masui. Apr 2005;54(4):418-9. [Medline].

  13. Prihoda JS, Davis LE. Metabolic emergencies in obstetrics. Obstet Gynecol Clin North Am. Jun 1991;18(2):301-18. [Medline].

  14. Rosenberg IN. Thyroid storm. N Engl J Med. Nov 5 1970;283(19):1052-3. [Medline].

  15. Scholz GH, Hagemann E, Arkenau C, Engelmann L, Lamesch P, Schreiter D. Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure?. Thyroid. Oct 2003;13(10):933-40. [Medline].

  16. Tietgens ST, Leinung MC. Thyroid storm. Med Clin North Am. Jan 1995;79(1):169-84. [Medline].

  17. Tintillani JE, Kelen GD, Stapazynski JS. Emergency Medicine A Comprehensive Study Guide. 5th ed. McGraw-Hill;1999:1343-1345.

  18. Utiger RD. The thyroid physiology; hyperthyroidism, hypothyroidism, and the painful thyroid. In: Endocrinology and Metabolism. 2nd ed. New York, NY: McGraw-Hill;1987:438.

  19. Wing DA, Millar LK, Koonings PP, et al. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol. Jan 1994;170(1 Pt 1):90-5. [Medline].

Previous
Next
 
Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy. T4 is levothyroxine. T3 is triiodothyronine.
Table. Symptoms and Signs of Thyroid Storm When Compared with Uncomplicated Thyrotoxicosis
Uncomplicated ThyrotoxicosisThyroid Storm
1. Heat intolerance, diaphoresis1. Hyperpyrexia, temperature in excess of 106o C, dehydration
2. Sinus tachycardia, heart rate 100-1402. Heart rate faster than 140 beats/min, hypotension, atrial dysrhythmias, congestive heart failure
3. Diarrhea, increased appetite with loss of weight3. Nausea, vomiting, severe diarrhea, abdominal pain, hepatocellular dysfunction-jaundice
4. Anxiety, restlessness4. Confusion, agitation, delirium, frank psychosis, seizures, stupor or coma
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.